Physician profile
Naz Rizvi
NPI 1417307901
$2,384.61
in general payments reported to CMS, 2019-2025
12 companies · $257 in 2025
The $257 reported for 2025 was more than what a typical Optometrist provider received nationally (typical 2025 total: $204).
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2019: $141 · 2020: $196 · 2021: $598 · 2022: $376 · 2023: $244 · 2024: $573 · 2025: $257.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Food and Beverage: $1,074.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Food and Beverage | $1,073.69 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Bausch & Lomb Americas INC. | $607.71 | 2022-2025 | Infuse, Miebo |
| Bausch & Lomb, A Division of Bausch Health US, LLC | $299.20 | 2019-2021 | |
| Eyevance Pharmaceuticals LLC | $228.39 | 2021 | |
| Glaukos Corporation | $179.44 | 2024 | Ce-Marked Kxla System |
| Coopervision INC. | $169.69 | 2021-2024 | Myday Contact Lens |
| Harrow Eye, LLC | $163.08 | 2024 | Iheezo |
| Novartis Pharmaceuticals Corporation | $143.32 | 2019-2020 | |
| Alcon Vision LLC | $140.65 | 2022-2025 | Precision7 |
| Johnson & Johnson Vision Care, INC. | $126.61 | 2021 | |
| Dompe US, INC. | $121.12 | 2023 | Oxervate |
| Horizon Therapeutics Plc | $110.28 | 2021 | |
| Sight Sciences, INC. | $95.12 | 2022 |
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw Naz Rizvi listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.